Neal D. Shore, MD, FACS, presented “HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer” for the Grand Rounds in Urology audience in June, 2020.
HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer – Summary:
Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center, presents the key aspects of the HERO phase 3 trial. The HERO trial looked at Relugolix, an oral GnRH receptor antagonist, versus Leuprolide Acetate for the treatment of advanced prostate cancer. He begins by going over the study design, patient demographics, and clinical characteristics. He then goes over some of the study’s key and secondary endpoints, all of which were met.
In this interview, Celestia S. Higano, MD, Professor of Medicine at the University of Washington School of Medicine and section editor of the ADT Next Generation Learning Center on Grand Rounds in Urology, asks Dr. Shore follow-up questions about the HERO trial’s findings, and the implications that this exciting new development in prostate cancer treatment could have in the field of urology.
How to cite: Shore, Neal D. “HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer” June, 2020. Accessed Nov 2024. https://dev.grandroundsinurology.com/tmprss2-ace-2-and-the-potential-role-of-5aris-and-gnrh-analogues-in-inhibiting-covid-19-infection/
ABOUT THE AUTHOR
Celestia (Tia) S. Higano, MD, FACP, was formerly a Professor in the Departments of Medicine and Urology, Division of Medical Oncology at the University of Washington, and Clinical Division of Fred Hutchison Cancer Research Center. She is an Adjunct Professor in the Department of Urologic Sciences at the University of British Columbia. She has been the Medical Director of the Prostate Cancer Supportive Care Program at the Vancouver Prostate Centre since 2013.
Dr. Higano received her medical degree from the University of Massachusetts Medical School and completed her residency at the Mayo Graduate School of Medicine in Rochester, MN. She was an oncology fellow under E. Donnall Thomas and Robert B. Livingston at the Fred Hutchison Cancer Research Center and the University of Washington.
Dr. Higano is an internationally renowned expert and clinical researcher focusing on prostate cancer. At UW, she led the prostate cancer clinical research group that participated in developing agents such as zoledronic acid, sipuleucel-T, enzalutamide, apalutamide, abiraterone, radium 223. Over these years, her clinical research has impacted the standards of care for patients with prostate cancer. She is a passionate educator and mentor and has guided many fellows and young faculty at the University of Washington and elsewhere who have chosen an academic career in GU Oncology.
